ERBB2 and cancer: Even if young women with breast cancer are more likely to have genetic predisposition with BRCA1 and BRCA2 mutations, the expression of key biomarkers ER, PR, and HER2/Neu and proliferation markers like Ki67 appears to be different compared to postmenopausal cancers, confirming the above findings [11, 44, 45].